Abstract:Objective:To measure expression levels of programmed death ligand 1 (PD-L1) in biopsy specimens of advanced lung adenocarcinomas, and to analyze its effect on the targeted therapy in lung cancer patients with epidermal growth factor receptor (EGFR)-positive.Methods:This was a case-control study.A total of 80 patients diagnosed asstage ⅢB/Ⅳ lung adenocarcinomas from January 2021 to December 2021 in Ruijin Hospital (northern hospital area) affiliated to Shanghai Jiaotong University Medical College were retrospectively recruited by non-random sampling.Expression levels of PD-L1 were measured by the PD-L1 IHC 22C3 pharmDx.The positive percentage score (TPS) of cells positively expressing PD-L1 was calculated as follows: positive, ≥1%; strong positive, ≥50%.Driving genes of lung cancer were detected by Amplification refractory mutation system-polymerase chain reaction (ARMS-PCR), including the EGFR, KRAS, ALK, ROS, MET, RET, BRAF, HER2 and PIK3CA.Thirty patients with EGFR gene sensitive mutations who were treated with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in our hospital until the disease progressed were followed up for at least 6 months.Results:The positive expression rate of PD-L1 (TPS≥1%) in advanced lung adenocarcinomas was 32.50% (26/80), of which 15% (12/80) were strongly positive (TPS≥50%).The positive rate of driver genes in lung cancer patients was 75% (60/80), including 46/80 (57.50%) with EGFR gene mutations, 7/80 (8.75%) with KRAS gene mutations, and 5/80 (6.25%) with mutations of other fusion genes (ALK, ROS and MET).The positive expression rate of PD-L1 in lung cancer patients with mutations of driver genes was significantly lower than those of lung cancer patients with wild-type driver genes [26.67% (16/60) vs 50.0% (10/20), χ2=3.72, P=0.027].PD-L1 was detected in 26.09% (12/46), 28.57% (2/7) and 60.00% (3/5) of lung cancer patients with positive EGFR, KRAS and fusion genes (ALK, ROS and MET), which were common driving genes of lung cancer.Thirty lung cancer patients with EGFR gene sensitive mutations received the first-line EGFR-TKI therapy in Ruijin hospital north, and the median progression-free survival (PFS) in those with positive PD-L1 was significantly shorter than the negative-PD-L1 cohort (2.0 months vs 11.0 months, P=0.018). Conclusions:PD-L1 is up-regulated in lung cancer patients with wild-type driver genes, fusion genes are higher in those with positive fusion gene mutations than those of other driver gene mutations.Lung cancer patients with positive PD-L1 and EGFR gene mutations have higher risk of primary resistance to the EGFR-TKI.Our results should be further validated in large-scale studies.

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer

The Predictive And Prognostic Effects Of Pd-L1 Expression On Tki Treatment And Survival Of Egfr-Mutant Nsclc A Meta-Analysis

[A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs]

Impact of programmed death-ligand 1 expression on the patients of stage IV non-small cell lung cancer harboring epidermal growth factor receptor mutation: a systematic review and meta-analysis

Effect of Strong Programmed Cell Death Ligand-1 (PD-L1) Expressions on Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Third-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations

Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue

Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials

Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors

Progress in the Study on PD-L1 Inhibitor in the Treatment of EGFR-Mutant Non-Small Cell Lung Cancer

Association of PD-L 1 expression with clinicopathologic features and overall survival in patients with non-small-cell lung cancer

Optimizing First-Line TKI Treatment Efficacy in PD-L1-positive EGFR-mutated NSCLC: the Impact of Antiangiogenic Agents

Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs

PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort

The Association of PD-L1 Expression with the Efficacy of Anti-Pd-1/pd-l1 Immunotherapy and Survival of Non-Small Cell Lung Cancer Patients: a Meta-Analysis of Randomized Controlled Trials

Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.

Expression level of PD-L1 in advanced lung adenocarcinoma and its clinical significance in EGFR-targeted therapy

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC

PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression

Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer

Effect on Non-Small Cell Lung Cancer After Combination of Driver Gene Mutations and Anti-PD -1/PD-L1 Immunotherapy as Well as Chemotherapy